English
简体中文
Total: £ 56.28
Published Date: 2025-11-05 | Pages: 146 | Tables: 152 | Medical Care
The global Chronic Spontaneous Urticaria Drug Treatment market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, is defined as the presence of urticaria most of the time during a week and this condition lasts for 6 weeks or more. About 40% of patients are accompanied by angioedema. The standard treatment for CSU is mainly second-generation H1 antihistamines, often at higher than conventional doses, combined with H2 antihistamines and leukotriene modulators.
CSU is a chronic inflammatory skin disease characterized by the sudden onset of hives and/or deep swelling of the skin. Despite standard of care treatments, patients with CSU often experience symptoms such as persistent itching or burning sensations that can be debilitating and significantly impact quality of life. Swelling usually occurs on the face, hands, and feet and can also affect the throat and upper respiratory tract. CSU is commonly treated with antihistamines, but in patients with limited available treatment options, the condition remains uncontrolled in up to 50% of patients.
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Chronic Spontaneous Urticaria Drug Treatment market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Mylan N. V.
Sanofi
GlaxoSmithKline
Bayer
Merck
Aurobindo Pharma
Hikma Pharmaceuticals
WOCKHARDT
AbbVie, Inc.
Cipla Inc.
F. Hoffmann La Roche Ltd.
Teva Pharmaceutical Industries, Ltd.
Pfizer, Inc.
Novartis AG
Eli Lilly and Company
Allergan
Lupin
Segment by Type
Antihistamine
Dupixent
Other
Segment by Application
Children
Adult
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Chronic Spontaneous Urticaria Drug Treatment study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Chronic Spontaneous Urticaria Drug Treatment: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Chronic Spontaneous Urticaria Drug Treatment Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Antihistamine
1.2.3 Dupixent
1.2.4 Other
1.3 Market Segmentation by Application
1.3.1 Global Chronic Spontaneous Urticaria Drug Treatment Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Children
1.3.3 Adult
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Chronic Spontaneous Urticaria Drug Treatment Revenue Estimates and Forecasts 2020-2031
2.2 Global Chronic Spontaneous Urticaria Drug Treatment Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Chronic Spontaneous Urticaria Drug Treatment Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Chronic Spontaneous Urticaria Drug Treatment Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Antihistamine Market Size by Players
3.3.2 Dupixent Market Size by Players
3.3.3 Other Market Size by Players
3.4 Global Chronic Spontaneous Urticaria Drug Treatment Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Chronic Spontaneous Urticaria Drug Treatment Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Chronic Spontaneous Urticaria Drug Treatment Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Chronic Spontaneous Urticaria Drug Treatment Market Size by Type (2020-2031)
6.4 North America Chronic Spontaneous Urticaria Drug Treatment Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Chronic Spontaneous Urticaria Drug Treatment Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Chronic Spontaneous Urticaria Drug Treatment Market Size by Type (2020-2031)
7.4 Europe Chronic Spontaneous Urticaria Drug Treatment Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Chronic Spontaneous Urticaria Drug Treatment Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Size by Type (2020-2031)
8.4 Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Chronic Spontaneous Urticaria Drug Treatment Market Size by Type (2020-2031)
9.4 Central and South America Chronic Spontaneous Urticaria Drug Treatment Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Chronic Spontaneous Urticaria Drug Treatment Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Chronic Spontaneous Urticaria Drug Treatment Market Size by Type (2020-2031)
10.4 Middle East and Africa Chronic Spontaneous Urticaria Drug Treatment Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Chronic Spontaneous Urticaria Drug Treatment Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Mylan N. V.
11.1.1 Mylan N. V. Corporation Information
11.1.2 Mylan N. V. Business Overview
11.1.3 Mylan N. V. Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.1.4 Mylan N. V. Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.1.5 Mylan N. V. Chronic Spontaneous Urticaria Drug Treatment Revenue by Product in 2024
11.1.6 Mylan N. V. Chronic Spontaneous Urticaria Drug Treatment Revenue by Application in 2024
11.1.7 Mylan N. V. Chronic Spontaneous Urticaria Drug Treatment Revenue by Geographic Area in 2024
11.1.8 Mylan N. V. Chronic Spontaneous Urticaria Drug Treatment SWOT Analysis
11.1.9 Mylan N. V. Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.2.4 Sanofi Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Chronic Spontaneous Urticaria Drug Treatment Revenue by Product in 2024
11.2.6 Sanofi Chronic Spontaneous Urticaria Drug Treatment Revenue by Application in 2024
11.2.7 Sanofi Chronic Spontaneous Urticaria Drug Treatment Revenue by Geographic Area in 2024
11.2.8 Sanofi Chronic Spontaneous Urticaria Drug Treatment SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.3.4 GlaxoSmithKline Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.3.5 GlaxoSmithKline Chronic Spontaneous Urticaria Drug Treatment Revenue by Product in 2024
11.3.6 GlaxoSmithKline Chronic Spontaneous Urticaria Drug Treatment Revenue by Application in 2024
11.3.7 GlaxoSmithKline Chronic Spontaneous Urticaria Drug Treatment Revenue by Geographic Area in 2024
11.3.8 GlaxoSmithKline Chronic Spontaneous Urticaria Drug Treatment SWOT Analysis
11.3.9 GlaxoSmithKline Recent Developments
11.4 Bayer
11.4.1 Bayer Corporation Information
11.4.2 Bayer Business Overview
11.4.3 Bayer Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.4.4 Bayer Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.4.5 Bayer Chronic Spontaneous Urticaria Drug Treatment Revenue by Product in 2024
11.4.6 Bayer Chronic Spontaneous Urticaria Drug Treatment Revenue by Application in 2024
11.4.7 Bayer Chronic Spontaneous Urticaria Drug Treatment Revenue by Geographic Area in 2024
11.4.8 Bayer Chronic Spontaneous Urticaria Drug Treatment SWOT Analysis
11.4.9 Bayer Recent Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Business Overview
11.5.3 Merck Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.5.4 Merck Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.5.5 Merck Chronic Spontaneous Urticaria Drug Treatment Revenue by Product in 2024
11.5.6 Merck Chronic Spontaneous Urticaria Drug Treatment Revenue by Application in 2024
11.5.7 Merck Chronic Spontaneous Urticaria Drug Treatment Revenue by Geographic Area in 2024
11.5.8 Merck Chronic Spontaneous Urticaria Drug Treatment SWOT Analysis
11.5.9 Merck Recent Developments
11.6 Aurobindo Pharma
11.6.1 Aurobindo Pharma Corporation Information
11.6.2 Aurobindo Pharma Business Overview
11.6.3 Aurobindo Pharma Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.6.4 Aurobindo Pharma Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.6.5 Aurobindo Pharma Recent Developments
11.7 Hikma Pharmaceuticals
11.7.1 Hikma Pharmaceuticals Corporation Information
11.7.2 Hikma Pharmaceuticals Business Overview
11.7.3 Hikma Pharmaceuticals Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.7.4 Hikma Pharmaceuticals Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.7.5 Hikma Pharmaceuticals Recent Developments
11.8 WOCKHARDT
11.8.1 WOCKHARDT Corporation Information
11.8.2 WOCKHARDT Business Overview
11.8.3 WOCKHARDT Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.8.4 WOCKHARDT Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.8.5 WOCKHARDT Recent Developments
11.9 AbbVie, Inc.
11.9.1 AbbVie, Inc. Corporation Information
11.9.2 AbbVie, Inc. Business Overview
11.9.3 AbbVie, Inc. Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.9.4 AbbVie, Inc. Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.9.5 AbbVie, Inc. Recent Developments
11.10 Cipla Inc.
11.10.1 Cipla Inc. Corporation Information
11.10.2 Cipla Inc. Business Overview
11.10.3 Cipla Inc. Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.10.4 Cipla Inc. Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 F. Hoffmann La Roche Ltd.
11.11.1 F. Hoffmann La Roche Ltd. Corporation Information
11.11.2 F. Hoffmann La Roche Ltd. Business Overview
11.11.3 F. Hoffmann La Roche Ltd. Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.11.4 F. Hoffmann La Roche Ltd. Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.11.5 F. Hoffmann La Roche Ltd. Recent Developments
11.12 Teva Pharmaceutical Industries, Ltd.
11.12.1 Teva Pharmaceutical Industries, Ltd. Corporation Information
11.12.2 Teva Pharmaceutical Industries, Ltd. Business Overview
11.12.3 Teva Pharmaceutical Industries, Ltd. Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.12.4 Teva Pharmaceutical Industries, Ltd. Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.12.5 Teva Pharmaceutical Industries, Ltd. Recent Developments
11.13 Pfizer, Inc.
11.13.1 Pfizer, Inc. Corporation Information
11.13.2 Pfizer, Inc. Business Overview
11.13.3 Pfizer, Inc. Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.13.4 Pfizer, Inc. Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.13.5 Pfizer, Inc. Recent Developments
11.14 Novartis AG
11.14.1 Novartis AG Corporation Information
11.14.2 Novartis AG Business Overview
11.14.3 Novartis AG Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.14.4 Novartis AG Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.14.5 Novartis AG Recent Developments
11.15 Eli Lilly and Company
11.15.1 Eli Lilly and Company Corporation Information
11.15.2 Eli Lilly and Company Business Overview
11.15.3 Eli Lilly and Company Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.15.4 Eli Lilly and Company Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.15.5 Eli Lilly and Company Recent Developments
11.16 Allergan
11.16.1 Allergan Corporation Information
11.16.2 Allergan Business Overview
11.16.3 Allergan Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.16.4 Allergan Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.16.5 Allergan Recent Developments
11.17 Lupin
11.17.1 Lupin Corporation Information
11.17.2 Lupin Business Overview
11.17.3 Lupin Chronic Spontaneous Urticaria Drug Treatment Product Features and Attributes
11.17.4 Lupin Chronic Spontaneous Urticaria Drug Treatment Revenue and Gross Margin (2020-2025)
11.17.5 Lupin Recent Developments
12 Chronic Spontaneous Urticaria Drug TreatmentIndustry Chain Analysis
12.1 Chronic Spontaneous Urticaria Drug Treatment Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Chronic Spontaneous Urticaria Drug Treatment Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Chronic Spontaneous Urticaria Drug Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Chronic Spontaneous Urticaria Drug Treatment Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Chronic Spontaneous Urticaria Drug Treatment Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Chronic Spontaneous Urticaria Drug Treatment Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Chronic Spontaneous Urticaria Drug Treatment Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Chronic Spontaneous Urticaria Drug Treatment Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Chronic Spontaneous Urticaria Drug Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Chronic Spontaneous Urticaria Drug Treatment Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Chronic Spontaneous Urticaria Drug Treatment by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Spontaneous Urticaria Drug Treatment as of 2024)
Table 11. Global Chronic Spontaneous Urticaria Drug Treatment Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Chronic Spontaneous Urticaria Drug Treatment Companies Headquarters
Table 13. Global Chronic Spontaneous Urticaria Drug Treatment Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Chronic Spontaneous Urticaria Drug Treatment Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Chronic Spontaneous Urticaria Drug Treatment Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Chronic Spontaneous Urticaria Drug Treatment Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Chronic Spontaneous Urticaria Drug Treatment Revenue by Application (2026-2031) & (US$ Million)
Table 21. Chronic Spontaneous Urticaria Drug Treatment High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Chronic Spontaneous Urticaria Drug Treatment Growth Accelerators and Market Barriers
Table 25. North America Chronic Spontaneous Urticaria Drug Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Chronic Spontaneous Urticaria Drug Treatment Growth Accelerators and Market Barriers
Table 27. Europe Chronic Spontaneous Urticaria Drug Treatment Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Chronic Spontaneous Urticaria Drug Treatment Investment Opportunities and Key Challenges
Table 31. Central and South America Chronic Spontaneous Urticaria Drug Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Chronic Spontaneous Urticaria Drug Treatment Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Chronic Spontaneous Urticaria Drug Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Mylan N. V. Corporation Information
Table 35. Mylan N. V. Description and Major Businesses
Table 36. Mylan N. V. Product Features and Attributes
Table 37. Mylan N. V. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Mylan N. V. Revenue Proportion by Product in 2024
Table 39. Mylan N. V. Revenue Proportion by Application in 2024
Table 40. Mylan N. V. Revenue Proportion by Geographic Area in 2024
Table 41. Mylan N. V. Chronic Spontaneous Urticaria Drug Treatment SWOT Analysis
Table 42. Mylan N. V. Recent Developments
Table 43. Sanofi Corporation Information
Table 44. Sanofi Description and Major Businesses
Table 45. Sanofi Product Features and Attributes
Table 46. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Sanofi Revenue Proportion by Product in 2024
Table 48. Sanofi Revenue Proportion by Application in 2024
Table 49. Sanofi Revenue Proportion by Geographic Area in 2024
Table 50. Sanofi Chronic Spontaneous Urticaria Drug Treatment SWOT Analysis
Table 51. Sanofi Recent Developments
Table 52. GlaxoSmithKline Corporation Information
Table 53. GlaxoSmithKline Description and Major Businesses
Table 54. GlaxoSmithKline Product Features and Attributes
Table 55. GlaxoSmithKline Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. GlaxoSmithKline Revenue Proportion by Product in 2024
Table 57. GlaxoSmithKline Revenue Proportion by Application in 2024
Table 58. GlaxoSmithKline Revenue Proportion by Geographic Area in 2024
Table 59. GlaxoSmithKline Chronic Spontaneous Urticaria Drug Treatment SWOT Analysis
Table 60. GlaxoSmithKline Recent Developments
Table 61. Bayer Corporation Information
Table 62. Bayer Description and Major Businesses
Table 63. Bayer Product Features and Attributes
Table 64. Bayer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Bayer Revenue Proportion by Product in 2024
Table 66. Bayer Revenue Proportion by Application in 2024
Table 67. Bayer Revenue Proportion by Geographic Area in 2024
Table 68. Bayer Chronic Spontaneous Urticaria Drug Treatment SWOT Analysis
Table 69. Bayer Recent Developments
Table 70. Merck Corporation Information
Table 71. Merck Description and Major Businesses
Table 72. Merck Product Features and Attributes
Table 73. Merck Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Merck Revenue Proportion by Product in 2024
Table 75. Merck Revenue Proportion by Application in 2024
Table 76. Merck Revenue Proportion by Geographic Area in 2024
Table 77. Merck Chronic Spontaneous Urticaria Drug Treatment SWOT Analysis
Table 78. Merck Recent Developments
Table 79. Aurobindo Pharma Corporation Information
Table 80. Aurobindo Pharma Description and Major Businesses
Table 81. Aurobindo Pharma Product Features and Attributes
Table 82. Aurobindo Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Aurobindo Pharma Recent Developments
Table 84. Hikma Pharmaceuticals Corporation Information
Table 85. Hikma Pharmaceuticals Description and Major Businesses
Table 86. Hikma Pharmaceuticals Product Features and Attributes
Table 87. Hikma Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Hikma Pharmaceuticals Recent Developments
Table 89. WOCKHARDT Corporation Information
Table 90. WOCKHARDT Description and Major Businesses
Table 91. WOCKHARDT Product Features and Attributes
Table 92. WOCKHARDT Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. WOCKHARDT Recent Developments
Table 94. AbbVie, Inc. Corporation Information
Table 95. AbbVie, Inc. Description and Major Businesses
Table 96. AbbVie, Inc. Product Features and Attributes
Table 97. AbbVie, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. AbbVie, Inc. Recent Developments
Table 99. Cipla Inc. Corporation Information
Table 100. Cipla Inc. Description and Major Businesses
Table 101. Cipla Inc. Product Features and Attributes
Table 102. Cipla Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Cipla Inc. Recent Developments
Table 104. F. Hoffmann La Roche Ltd. Corporation Information
Table 105. F. Hoffmann La Roche Ltd. Description and Major Businesses
Table 106. F. Hoffmann La Roche Ltd. Product Features and Attributes
Table 107. F. Hoffmann La Roche Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. F. Hoffmann La Roche Ltd. Recent Developments
Table 109. Teva Pharmaceutical Industries, Ltd. Corporation Information
Table 110. Teva Pharmaceutical Industries, Ltd. Description and Major Businesses
Table 111. Teva Pharmaceutical Industries, Ltd. Product Features and Attributes
Table 112. Teva Pharmaceutical Industries, Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Teva Pharmaceutical Industries, Ltd. Recent Developments
Table 114. Pfizer, Inc. Corporation Information
Table 115. Pfizer, Inc. Description and Major Businesses
Table 116. Pfizer, Inc. Product Features and Attributes
Table 117. Pfizer, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Pfizer, Inc. Recent Developments
Table 119. Novartis AG Corporation Information
Table 120. Novartis AG Description and Major Businesses
Table 121. Novartis AG Product Features and Attributes
Table 122. Novartis AG Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Novartis AG Recent Developments
Table 124. Eli Lilly and Company Corporation Information
Table 125. Eli Lilly and Company Description and Major Businesses
Table 126. Eli Lilly and Company Product Features and Attributes
Table 127. Eli Lilly and Company Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Eli Lilly and Company Recent Developments
Table 129. Allergan Corporation Information
Table 130. Allergan Description and Major Businesses
Table 131. Allergan Product Features and Attributes
Table 132. Allergan Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Allergan Recent Developments
Table 134. Lupin Corporation Information
Table 135. Lupin Description and Major Businesses
Table 136. Lupin Product Features and Attributes
Table 137. Lupin Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Lupin Recent Developments
Table 139. Raw Materials Key Suppliers
Table 140. Distributors List
Table 141. Market Trends and Market Evolution
Table 142. Market Drivers and Opportunities
Table 143. Market Challenges, Risks, and Restraints
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Chronic Spontaneous Urticaria Drug Treatment Product Picture
Figure 2. Global Chronic Spontaneous Urticaria Drug Treatment Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Antihistamine Product Picture
Figure 4. Dupixent Product Picture
Figure 5. Other Product Picture
Figure 6. Global Chronic Spontaneous Urticaria Drug Treatment Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Children
Figure 8. Adult
Figure 9. Chronic Spontaneous Urticaria Drug Treatment Report Years Considered
Figure 10. Global Chronic Spontaneous Urticaria Drug Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 12. Global Chronic Spontaneous Urticaria Drug Treatment Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Chronic Spontaneous Urticaria Drug Treatment Revenue Market Share by Region (2020-2031)
Figure 14. Global Chronic Spontaneous Urticaria Drug Treatment Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. Antihistamine Revenue Market Share by Player in 2024
Figure 17. Dupixent Revenue Market Share by Player in 2024
Figure 18. Other Revenue Market Share by Player in 2024
Figure 19. Global Chronic Spontaneous Urticaria Drug Treatment Revenue Market Share by Type (2020-2031)
Figure 20. Global Chronic Spontaneous Urticaria Drug Treatment Revenue Market Share by Application (2020-2031)
Figure 21. North America Chronic Spontaneous Urticaria Drug Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 22. North America Top 5 Players Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) in 2024
Figure 23. North America Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) by Type (2020 - 2031)
Figure 24. North America Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 25. US Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 26. Canada Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 27. Mexico Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 28. Europe Chronic Spontaneous Urticaria Drug Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 29. Europe Top 5 Players Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) in 2024
Figure 30. Europe Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 31. Europe Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 32. Germany Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 33. France Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 34. U.K. Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 35. Italy Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 36. Russia Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Top 8 Players Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) in 2024
Figure 39. Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 40. Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 41. Indonesia Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 42. Japan Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 43. South Korea Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 44. Australia Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 45. India Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 46. Indonesia Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 47. Vietnam Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 48. Malaysia Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 49. Philippines Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 50. Singapore Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2031) & (US$ Million)
Figure 51. Central and South America Chronic Spontaneous Urticaria Drug Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Central and South America Top 5 Players Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) in 2024
Figure 53. Central and South America Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 54. Central and South America Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 55. Brazil Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2025) & (US$ Million)
Figure 56. Argentina Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2025) & (US$ Million)
Figure 57. Middle East and Africa Chronic Spontaneous Urticaria Drug Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Middle East and Africa Top 5 Players Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) in 2024
Figure 59. South America Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 60. Middle East and Africa Chronic Spontaneous Urticaria Drug Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 61. GCC Countries Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2025) & (US$ Million)
Figure 62. Israel Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2025) & (US$ Million)
Figure 63. Egypt Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2025) & (US$ Million)
Figure 64. South Africa Chronic Spontaneous Urticaria Drug Treatment Revenue (2020-2025) & (US$ Million)
Figure 65. Chronic Spontaneous Urticaria Drug Treatment Industry Chain Mapping
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
